Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

2.415 +0.155 (+6.86%)
Streaming Delayed Price Updated: 3:01 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use. 
Via Benzinga
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Which stocks are experiencing notable movement on Wednesday?
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later
Via Stocktwits
BioXcel Sparks Retail Frenzy As Stock Soars Ahead Of Phase 3 Results For Bipolar, Schizophrenia Drug
Via Stocktwits
BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label
Via Stocktwits
BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment
BioXcel's Phase 3 trial shows BXCL501 safely reduces agitation in schizophrenia patients, supporting plans for an FDA label expansion. 
Via Benzinga
The market is filled with gapping stocks in Wednesday's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Why MongoDB Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
BioXcel Stock Surges 19% In After-Hours Trading: What You Need To Know
BioXcel Therapeutics shares surged over 19% after hours ahead of key Phase 3 trial results for its at-home agitation treatment, sparking strong investor interest. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Tuesday's pre-market session: top gainers and losers
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!
Via AB Newswire
Topics Artificial Intelligence
BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On?
BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher. The AI biopharmaceutical company on Monday announced positive meeting comments from the U.S. Food and Drug Administration (FDA). 
Via Benzinga
Topics Artificial Intelligence
These stocks are moving in today's pre-market session
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label (This works)
The update comes as the company wraps up its pivotal Serenity At-Home Phase 3 trial and analysts grow more optimistic on BXCL501’s commercial potential. 
Via Stocktwits
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
3 Supercharged Stocks Flashing Strong Momentum Signals
Here's a look at some standout momentum movers that are just starting to pick up steam. 
Via Benzinga
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On?
Shares of BioXcel Therapeutics are trading sharply lower Tuesday morning. The company announced its financial results for Q2. 
Via Benzinga
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
These stocks are moving in today's after hours session
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.